home > pediatrics > mbrl > openpositions.html
Diploma Thesis Projects:
"Regulation of alternative Splicing by SF1 in cancer cells" (under the guidance of Dipl.Ing. Dr. Judith Hagenbuchner)
Start: Feb 2012
Contact: Judith.Hagenbuchner@i-med.ac.at
Aim: Studying the effect of the putative FOXO3 target SF1 on alternative splicing processes in cancer cells
Methodology: cell culture of neuroblastoma cells, retroviral and lentiviral gene transfer, quantitative RT-PCR, cloning and vector construction, immunoblot, flow cytometry and live cell fluorescence imaging.
This project is embedded in a larger project of the Pediatric Oncology Research Team and will be performed in part at the Tyrolean Cancer Research Institute.
"Developing a medium-throughput, robot-assisted screening system for the identification of small compounds that directly regulate the transcriptional activity of FOXO3" (under the guidance of Priv.Doz. Mag.Dr. Michael J. Ausserlechner)
Start: Feb 2012
Contact: Michael.J.Ausserlechner@i-med.ac.at
Aim: Development of renilla luciferase-expressing reporter cell lines to directly measure FOXO3 transcriptional activity in living tumor cells. This system shall be used to screen libraries of putative FOXO3-interacting candidate compounds to assess cell permeability, bioavailability and bioactivity.
Methodology: mammalian cell culture, retroviral and lentiviral gene transfer, quantitative RT-PCR, cloning and vector construction, immunoblot, flow cytometry and live cell imaging.
This project is embedded in a larger project of the Pediatric Oncology Research Team and will be performed in cooperation with the Tyrolean Cancer Research Institute and the Institute of Pharmacy, Computer-Aided Molecular Design Group.
"Development and evaluation of a novel technique for measuring the specific interaction of small drug like compounds to recombinant proteins" (under the guidance of Priv.Doz. Mag.Dr. Michael J. Ausserlechner)
Start: Feb 2012
Contact: Michael.J.Ausserlechner@i-med.ac.at
Aim: Development of a novel cost-effective technique to measure the interaction of small, drug-like compounds with protein targets produced and purified from E. coli. Validation of this technique using already established fluorescence polarization analysis and testing of identified compounds in cell culture models.
Methodology: production of recombinant proteins in E. coli, protein purification via FPLC, HRM-analysis, immunoblot, flow cytometry and live cell imaging.
This project is embedded in a larger project of the Pediatric Oncology Research Team and will be performed in cooperation with the Tyrolean Cancer Research Institute and the Institute of Pharmacy, Computer-Aided Molecular Design Group.
Molecular Biology Research Laboratory (MBRL)